BMRN: biomarin.com Expected earnings per share growth for next year

A stable liquidity surplus and high margins on orphan drugs create a reliable cash flow, which is confirmed by the projected earnings per share (EPS) for year n+1 for BioMarin Pharmaceutical (BMRN). The 112.50 metric determines this level. Sales growth for Voxzogo and acquisition potential drive development, although management faces pressure from shareholders demanding the minimization of trial risks and an accelerated path to sustainable profitability.

BioMarin Pharmaceutical Inc. (BMRN): Net earnings per share change forecast for next year from 07/04/2022 to 11/15/2026

Analytical breakdowns and data insights for company BioMarin Pharmaceutical Inc. (BMRN)

- share price and consensus valuation forecast:

Stock Price BioMarin|BMRN - Broker Consensus Forecast

- market capitalization information:

Market Valuation BioMarin Pharma|BMRN - Value Adjusted for Debt and Cash

- book capitalization information:

Net Assets per Single Share BioMarin|BMRN - Net Asset Value|Market Capitalization to Book Value Ratio biomarin.com|BMRN - Aggregate Asset Value

- company total debt and liquidity indicators:

- net income and valuation ratios data:

BMRN - Company Net Income|Projected Future Earnings BioMarin Pharmaceutical|BMRN - Business Payback Period|Future Price to Earnings BioMarin Corp|BMRN - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BioMarin Pharma|BMRN - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) BioMarin|BMRN - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months biomarin.com|BMRN - Earnings per share increase in current year|Earnings growth forecast for next year BioMarin Pharmaceutical

- sales revenue and business income indicators:

BMRN - Company Gross Revenue|Company Projected Revenue BioMarin|BMRN - Market Cap to Revenue Ratio|Forward Price-to-Revenue Multiple BioMarin Pharma|BMRN - Revenue Dynamics YoY (Last Twelve Months)

Fundamental company valuation:BMRN, biomarin.com

Fundamental asset selection is based on a business's ability to generate excess profit in the future. This indicator measures the expected earnings per share (EPS) trend, reflecting the market consensus regarding net income growth rates. For BioMarin Pharmaceutical (BMRN), this metric confirms the effectiveness of transitioning toward the commercial scaling of orphan drugs rather than risky development projects. The EPS consensus forecast vector on the GURU.Markets platform allows for a real-time assessment of the current portfolio restructuring's success.

Analysis of competing companies